Research ArticleClinical Studies

What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?

RHIAN SIÂN DAVIES, CHRISTIAN SMITH, MICHAEL ROBERT BUTTON, JACOB TANGUAY, JIM BARBER, NACHIAPPAN PALANIAPPAN, JOHN STAFFURTH and JASON FRANCIS LESTER
Anticancer Research October 2015, 35 (10) 5615-5621;

Article Information

vol. 35 no. 10 5615-5621
PMID 
26408734
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 9, 2015
  • Revision received July 9, 2015
  • Accepted July 13, 2015
  • Published online September 25, 2015.
Copyright & Usage 
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. RHIAN SIÂN DAVIES1⇑,
  2. CHRISTIAN SMITH1,
  3. MICHAEL ROBERT BUTTON1,
  4. JACOB TANGUAY1,
  5. JIM BARBER1,
  6. NACHIAPPAN PALANIAPPAN1,
  7. JOHN STAFFURTH1,2 and
  8. JASON FRANCIS LESTER1
  1. 1Velindre Cancer Centre, Cardiff, Wales, U.K.
  2. 2Institute of Cancer Genetics, Cardiff University, Cardiff, Wales, U.K.
  1. Correspondence to: Dr. Rhian Sian Davies, Velindre Cancer Centre, Cardiff, Wales, U.K. Tel: +44 2920615888, e-mail: rhian.s.davies{at}wales.nhs.uk
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
RHIAN SIÂN DAVIES, CHRISTIAN SMITH, MICHAEL ROBERT BUTTON, JACOB TANGUAY, JIM BARBER, NACHIAPPAN PALANIAPPAN, JOHN STAFFURTH, JASON FRANCIS LESTER
Anticancer Research Oct 2015, 35 (10) 5615-5621;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords